Arsenic Trioxide and Pixantrone Highlighted in 42 Abstracts and Presentations at The American Society of Hematology Meeting
Tuesday November 23, 7:00 am ET
Updates on two phase II pixantrone studies demonstrate high rates of complete responses
SEATTLE, Nov. 23 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) announced today that clinical investigators from cancer research centers will report data from recent and ongoing clinical trials of arsenic trioxide (TRISENOX®) and pixantrone in a broad range of hematologic cancers at the 46th Meeting of the American Society of Hematology (ASH) from December 4-7 in San Diego, Calif. Data on arsenic trioxide will be presented in the treatment of leukemia, multiple myeloma and myelodysplasia. Two phase II studies will provide updated information on the potential clinical activity of pixantrone in non-Hodgkin's lymphoma.
The following are some of the clinical research abstracts on arsenic trioxide and pixantrone that will be presented in oral or poster sessions. For a complete list of arsenic trioxide and pixantrone presentations and abstracts at ASH, please refer to the CTI website at cticseattle.com . To access a complete list of abstracts at ASH, refer to the conference website at hematology.org.
Saturday, December 4, 2004, at 6:00 pm PT
Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in
Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the
Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin's
Lymphoma (NHL)-Poster Session
Dr. Luis Fayad, MD Anderson Cancer Center, Houston, TX
Saturday, December 4, 2004, at 6:00 pm PT
TRISENOX(R) (arsenic trioxide) in Patients with Myelodysplastic Syndromes
(MDS): Preliminary Results of a Phase I/II Study-Poster Session
Dr. Norbert Vey, Institut Paoli-Calmettes, Marseille, France
Sunday, December 5, 2004, at 6:00 pm PT
Preliminary Phase II Study Results of BBR2778 in Combination with
Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed
Aggressive Non-Hodgkins Lymphoma-Poster Session
Dr. Raoul Herbrecht, Hopital de Hautepierre, Strasbourg, France
Sunday, December 5, 2004, at 6:00 pm PT
A Phase I/II Multicenter, Safety and Efficacy Study of Combination
Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) in
Patients with Relapsed or Refractory Multiple Myeloma-Poster Session
Dr. James Berenson, Institute for Myeloma and Bone Marrow Cancer
Sunday, December 5, 2004, at 6:00 pm PT
Arsenic Trioxide (TRISENOX(R) ATO), Ascorbic Acid (AA) and Dexamethasone
(Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma
(MM) Patients (pts); a Final Report-Poster Session
Dr. Mohamad Hussein, Cleveland Clinic Foundation, Taussig Cancer Center
Monday, December, 6, 2004 at 1:30 pm PT
Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To
Eliminate or Minimize Use of Chemotherapy (CT) in Untreatable Acute
Promyelocytic Leukemia (APL)-Oral Session
Dr. Elihu Estey, The University of Texas, M. D. Anderson Cancer Center |
